FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

l	OMB APPROVAL									
	OMB Number:	3235-0287								
	Estimated average bu	ırden								

0.5

hours per response:

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

						or :	Section	on 30(n)	or the i	nvestmen	it Con	npany Act	01 194	40							
Name and Address of Reporting Person* COOKE MICHAEL P.						2. Issuer Name and Ticker or Trading Symbol Magenta Therapeutics, Inc. [MGTA]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
(Last) (First) (Middle) C/O MAGENTA THERAPEUTICS, INC. 100 TECHNOLOGY SQUARE, 5TH FLOOR					09/	3. Date of Earliest Transaction (Month/Day/Year) 09/12/2019										Office below	er (give title v) Chief Scien	r (give title Other (spec) below) Chief Scientific Officer		(specify	
(Street) CAMBRIDGE MA 02139 (City) (State) (Zip)						_ 4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)										dividual or Joint/Group Filing (Check Applicable) Form filed by One Reporting Person Form filed by More than One Reporting Person				
			Tabl	e I - Nor	ı-Deriv	ative	Se	curitie	s Acc	quired,	Dis	posed o	f, or	Bene	efici	ally O	wne	ed			
1. Title of Security (Instr. 3) 2. Transa Date (Month/D							Exe Day/Year) if a		A. Deemed xecution Date, any lonth/Day/Year)		Transaction Disposed Code (Instr. 5)		ities Acquired (A d Of (D) (Instr. 3,			ind S B O	5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership
										Code	v	Amount		(A) or (D)	Price	, т	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
common stock 09/12							9					844		D \$		12 264		64,679]	D	
			Та	ble II - D								sed of, onvertib					ned		,		
1. Title of Derivative Security (Instr. 3)	2. Conversi or Exerci Price of Derivativ Security	on i	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,		Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		8. Price Deriva Securi (Instr.	ivative urity	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	vnership rm: rect (D) Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)
						Code	,			Date Exercisal		Expiration Date	Amou or Numb of Title Share:		nber						

Explanation of Responses:

1. This trade is pursuant to an active 10b5-1 plan.

Remarks:

/s/ Zoran Zdraveski, Attorneyin-Fact for Michael P. Cooke 09/16/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.